Global Nanomedicine Market Report is recently published by Reports N Markets is a value addition to the studied Market. The compilation of the research report is conditioned by primary and secondary research techniques. The report also elaborates on factors that are fueling or hampering the growth of the current Global Nanomedicine Market. It focuses on recent trends and technologies that boost company performance. It also offers a panoramic view of the competitive landscape that will aid in differentiating competition at global and national level. To approximate risks and challenges involved, various business models have been presented.

Download Sample Copy of this Report: https://www.reportsnmarkets.com/request_sample.php?id=97555&utm_source=Blog&utm_medium=HS

It enumerates the financial aspects of the businesses such as profit margin, gross margin, market shares, and pricing structures. Business profiles of several top-level industries have been examined to get a clear idea about the successful strategies followed by them. The report is rich with illustrations like infographics, charts, tables, and pictures to generate a strong footing for detailed analysis of recent trends and technological advancements in the Global Nanomedicine Market.

Market Segment as follows:

Product Type Segmentation Includes

Regenerative Medicine

In-vitro & In-vivo Diagnostics

Vaccines

Drug Delivery

Application Segmentation Includes

Clinical Cardiology

Urology

Genetics

Orthopedics

Ophthalmology

Companies Includes

GE Healthcare

Johnson & Johnson

Mallinckrodt plc

Merck & Co. Inc.

Nanosphere Inc.

Pfizer Inc.

Sigma-Tau Pharmaceuticals Inc.

Smith & Nephew PLC

Stryker Corp

Teva Pharmaceutical Industries Ltd.

UCB (Union chimique belge) S.A

Get Best Discount on this Report: https://www.reportsnmarkets.com/ask_for_discount.php?id=97555&utm_source=Blog&utm_medium=HS

Table of Contents

Chapter 1 Global Nanomedicine Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Nanomedicine Market Competition by Companies

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Nanomedicine Market Analysis by Application

Chapter 8 Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Global Nanomedicine Market Effect Factors Analysis

Chapter 12 Global Nanomedicine Market Forecast

For More Information: https://www.reportsnmarkets.com/enquiry_before_buying.php?id=97555&utm_source=Blog&utm_medium=HS

Contact Us:

Reports N Markets,

125 High Street, Boston, MA 02110

sales@reportsnmarkets.com

https://www.reportsnmarkets.com

+1 617 671 0092

See the rest here:
Covid-19 Impact Analysis on Nanomedicine Market by Forecast to 2026 with Profiling Top Players GE Healthcare, Johnson & Johnson, Mallinckrodt...

SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic energetic capacity of motor neurons while simultaneouslyreducing oxidative stress.

As of the data cutoff (October 27, 2020), the trial was fully enrolled with a preliminary blinded assessment of the studys primary endpoint, the motor neuron number index-4 [MUNIX(4)] score, showing that more than 40% of enrolled patients with completed week 12 data experienced improvements in motor neuron function assessed by MUNIX. When compared to baseline values, the average MUNIX(4) score of the overall trial population (including both active CNM-Au8 and placebo) experienced an absolute increase in mean MUNIX(4) values. This increase exceeded the expectations of the statistical modeling on which the study was based, which predicted a linear decline in average MUNIX(4) score from study onset (Neuwirth et al. JNNP 2015). These data, while blinded, suggest that CNM-Au8 may have neuro-reparative potential in ALS patients. Clene expects to report the complete, unblinded results from the RESCUE-ALS study in 2H 2021.

Although blinded to treatment assignment, these data are encouraging. We believe Clenes breakthrough approach with the application of physics to biology via direct electron interactions within cellular systems at the nano-scale may hold the potential to revolutionize the treatment of neurodegenerative diseases such as ALS and other motor neuron diseases, said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.

Rob Etherington, President and CEO of Clene added, This blinded interim analysis suggests that CNM-Au8 is working mechanistically to address a foundational challenge common to many neurodegenerative diseases, namely that stressed or failing neurons need additional energy for their survival, repair, and improved function. Emerging MUNIX data potentially indicate preservation of motor units, which is promising. We eagerly anticipate final results and are encouraged that these blinded interim results may provide hope for ALS patients and their families as they search for new therapies to treat this devastating disease.

The presentation (CLT-23) titled, RESCUE-ALS Trial, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Patients: Design and Interim Blinded Results, is available as a live e-Poster on December 10th at 12:10 12:50 pm EST at the Virtual 31st International Symposium on ALS/MND, held online (https://symposium.mndassociation.org/virtual-2020/).

About RESCUE-ALSRESCUE-ALS is a Phase 2 multi-center, randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic with ALS (within 24-months of screening or 12-months from diagnosis). Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 (30 mg) or placebo in addition to their current standard of care. Participants will receive their randomized treatment over 36 consecutive weeks during the treatment period. The objective of this study is to assess the impact of improving neuronal bioenergetics, reducing reactive oxygen species and promoting protein homeostasis with CNM-Au8 to slow disease progression in patients with ALS. In the trial, efficacy is assessed as the average change in motor neuron unit number index (MUNIX) estimated by electromyography for the abductor digiti minimi (ADM), abductor pollicis brevis (APB), biceps brachii (BB), and tibialis anterior (TA) (muscles of the hand, arm, and leg). The trial was fully enrolled with 44 participants as of the reported 27-October-2020 data cut. Baseline characteristics include [mean (SD)], MUNIX(4) score: 93.7 (45.8); FVC % predicted: 80.8 (16.3); ALSFRS-R: 38.6 (6.1); ALSSQOL-20: 3.3 (1.3), mean time from diagnosis: 4.7 (4.6) months; riluzole background treatment, 92%.

About CNM-Au8CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of pure gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, multiple sclerosis, and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.

About ALSALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About CleneClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

Forward-Looking StatementsThis press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Form S-4 filed by Chelsea Worldwide (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission (SEC) made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactAndrew MielachLifeSci Communications(646) 876-5868amielach@lifescicomms.com

Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com

See original here:
Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide...

This article was originally published here

Curr Med Chem. 2020 Dec 28. doi: 10.2174/0929867328666201228124038. Online ahead of print.

ABSTRACT

Prostate cancer is the fifth cause of tumor-related deaths in man worldwide. Due to its long latency period, this pathology represents an ideal type of disease for chemopreventive studies. Among the drugs considered thus far for the treatment of prostate cancer, the natural compound resveratrol emerged as very promising. Resveratrol is a widely recognized as chemopreventive agent and was shown to potentiate the antitumor activity of conventional chemotherapeutics in several tumors, including prostate cancer. Here we overview the literature of the last five years and summarize the recent achievements of resveratrol and its derivatives as antimetastatic agents in prostate cancer. Moreover, drug combination studies as well as nanomedicine approaches proposed to improve resveratrol activity and to overcome delivery drawbacks are addressed. The last part of the review discusses the clinical trials containing resveratrol ongoing on cancer patients.

PMID:33371831 | DOI:10.2174/0929867328666201228124038

View original post here:
Resveratrol and prostate cancer: the power of phytochemicals - DocWire News

Dongki Yang

Department of Physiology, College of Medicine, Gachon University, Incheon, 21999, South Korea

Correspondence: Dongki YangDepartment of Physiology, College of Medicine, Gachon University, Incheon 21999, South KoreaTel +82-32-899-6072Fax +82-32-899-6588Email dkyang@gachon.ac.kr

Abstract: COVID-19, caused by SARS-CoV-2 infection, has been prevalent worldwide for almost a year. In early 2000, there was an outbreak of SARS-CoV, and in early 2010, a similar dissemination of infection by MERS-CoV occurred. However, no clear explanation for the spread of SARS-CoV-2 and a massive increase in the number of infections has yet been proposed. The best solution to overcome this pandemic is the development of suitable and effective vaccines and therapeutics. Fortunately, for SARS-CoV-2, the genome sequence and protein structure have been published in a short period, making research and development for prevention and treatment relatively easy. In addition, intranasal drug delivery has proven to be an effective method of administration for treating viral lung diseases. In recent years, nanotechnology-based drug delivery systems have been applied to intranasal drug delivery to overcome various limitations that occur during mucosal administration, and advances have been made to the stage where effective drug delivery is possible. This review describes the accumulated knowledge of the previous SARS-CoV and MERS-CoV infections and aims to help understand the newly emerged SARS-CoV-2 infection. Furthermore, it elucidates the achievements in developing COVID-19 vaccines and therapeutics to date through existing approaches. Finally, the applicable nanotechnology approach is described in detail, and vaccines and therapeutic drugs developed based on nanomedicine, which are currently undergoing clinical trials, have presented the potential to become innovative alternatives for overcoming COVID-19.

Keywords: COVID-19, SARS-CoV-2, antiviral drug, vaccines, nanoparticles, nanotechnology

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Application of Nanotechnology in the COVID-19 Pandemic | IJN - Dove Medical Press

Healthcare Nanotechnology (Nanomedicine) Market report delivers an overview of the market trends, drivers, and barriers with respect to the competitive landscape. It also provides a detailed overview of the market of different regions globally.Furthermore, the Healthcare Nanotechnology (Nanomedicine) market report contains a primary overview of the Healthcare Nanotechnology (Nanomedicine) market covering different product definitions, classifications, and participants in the industry chain structure.

The global Healthcare Nanotechnology (Nanomedicine) market provides quantitative and qualitative analysis of the competitive landscape, development trends, and key success in the Healthcare Nanotechnology (Nanomedicine) industry.

Competitor Landscape: Healthcare Nanotechnology (Nanomedicine) market report contains top companies on the basis of types, applications, size, share, and regions.

Inquire or Share Your Questions If Any Before the Purchasing This Report https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

Reason to buy Healthcare Nanotechnology (Nanomedicine) Market Report:

Purchase this Report (Price 4250 USD for a Single-User License) https://www.industryresearch.co/purchase/14099195

Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market 2020-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Hyoscine-N-Butyl Bromide Market Size and Share Outlook 2020 to 2026 | Key Developments Trends, Growth Factors, Business Status and Regional Analysis

Property Management System in Hotel Market Growth Share 2020 Regional Trends, Market Overview with Key Players, Industry Size, Demand Status Forecast to 2025 | Report by Industry Research.co

Wood Ceilings Market Share and Business Development 2020 Future Plans of Top Companies, Growth Size, Industry Share by Latest Trends Forecast to 2025

PBT Engineering Plastics Market Growth Opportunities by Key Players 2020 | Evolving Technologies, Market Dynamics, Global Size, Industry Share Analysis till 2026 Report by Industry Research.co

Ethylene Methacrylic Acid (EMA) Market Size, Share, Top Manufacturers 2020 Future Growth Rate, Industry Trends, Business Strategy, Demand Status by 2026 With COVID-19 Analysis

Rangefinders Market Growth Factors by Latest Developments 2020 | Future Demand Status, Business Strategies, Opportunities, Trends, Industry Size and Share Forecast to 2026

IVF Devices and Consumables Market 2020 | by Growing Factors, Size, Global Opportunities by Leading Players, Top Countries Data, Demand Status, Regional Overview by CAGR Value, and Share Analysis till 2026

Dental Carts Market Size Analysis by Latest Trends 2020 | Global Industry Growth Factors, Revenue, CAGR Status, Leading Key Players Update, Business Share by Regions Forecast to 2026

Epigenetics Drugs and Diagnostic Technologies Market Size by Growth Scenario 2020 Trend Analysis, Industry Status by Manufacturers, Business Share, Future Scope and Global Opportunities Forecast to 2026

Deep Brain Stimulation (DBS) Devices Market Size, Share Analysis 2020 Global Analysis by Key Players, Growth Overview, Type and Applications by Regions Forecast to 2025 | Industry Research.co

Cholesterol Lowering Biologic Drugs Market Size by Future Scope 2020 | Global Industry Revenue, Share, Future Demand Status, Growth Segmentations Analysis by Regions Forecast to 2026

Beeswax Market Growth Share 2020 Regional Trends, Market Overview with Key Players, Industry Size, Demand Status Forecast to 2025 | Report by Industry Research.co

Read the rest here:
Healthcare Nanotechnology (Nanomedicine) Market 2020 with Growth, Share, Demand, Global Production with Revenue Share, and Applications Forecast to...

The "Nanomedicine Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.

This report describes the global market size of Nanomedicine from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025. For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.

For the competitor segment, the report includes global key players of Nanomedicine as well as some small players.

The information for each competitor includes:

Company Profile

Main Business Information

SWOT Analysis

Sales, Revenue, Price and Gross Margin

Market Share

Applications Segment:

Cancer Detection

Monitoring Therapy

Disease Detection

Companies Covered:

Abbott Laboratories

Cepheid

Philips

GE Healthcare

Siemens

Gen-Proberporated

MDxHealth SA

EpiGenomics AG

Roche Diagnostics

Sequenom

Manhattan Scientifics

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter 4 Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End-users

Chapter 5 Market Trend Analysis

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

Chapter 6 Industry Chain Analysis

6.1 Upstream/Suppliers Analysis

6.2 Nanomedicine Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End-users

Chapter 7 Latest Market Dynamics

7.1 Latest News

7.2 Merger and Acquisition

7.3 Planned/Future Project

7.4 Policy Dynamics

Chapter 8 Trading Analysis

8.1 Export of Nanomedicine by Region

8.2 Import of Nanomedicine by Region

8.3 Balance of Trade

Chapter 9 Historical and Forecast Nanomedicine Market in North America (2015-2025)

9.1 Nanomedicine Market Size

9.2 Nanomedicine Demand by End Use

Story continues

9.3 Competition by Players/Suppliers

9.4 Type Segmentation and Price

9.5 Key Countries Analysis

9.5.1 US

9.5.2 Canada

9.5.3 Mexico

Chapter 10 Historical and Forecast Nanomedicine Market in South America (2015-2025)

10.1 Nanomedicine Market Size

10.2 Nanomedicine Demand by End Use

10.3 Competition by Players/Suppliers

10.4 Type Segmentation and Price

10.5 Key Countries Analysis

10.5.1 Brazil

10.5.2 Argentina

10.5.3 Chile

10.5.4 Peru

Chapter 11 Historical and Forecast Nanomedicine Market in Asia & Pacific (2015-2025)

11.1 Nanomedicine Market Size

11.2 Nanomedicine Demand by End Use

11.3 Competition by Players/Suppliers

11.4 Type Segmentation and Price

11.5 Key Countries Analysis

11.5.1 China

11.5.2 India

11.5.3 Japan

11.5.4 South Korea

11.5.5 Asean

11.5.6 Australia

Chapter 12 Historical and Forecast Nanomedicine Market in Europe (2015-2025)

12.1 Nanomedicine Market Size

12.2 Nanomedicine Demand by End Use

12.3 Competition by Players/Suppliers

12.4 Type Segmentation and Price

12.5 Key Countries Analysis

12.5.1 Germany

12.5.2 France

Read more:
Global Nanomedicine Market Analysis and Forecast to 2025 by Cancer Detection, Monitoring Therapy & Disease Detection - ResearchAndMarkets.com -...

A new intelligence report Nanomedicine Market Was recently added to Nanomedicine Market Research collection of top-line market study reports. International Nanomedicine Market report is a meticulous all-inclusive analysis of this market that provides access to direct firsthand insights on the growth trail of market at near term and long term. On the grounds of factual advice sourced from authentic industry pros and extensive primary business study, the report offers insights about the historical growth pattern of Nanomedicine Market and present market situation. It then provides brief and long-term market growth projections.

Projections are only based on the comprehensive analysis of key Market dynamics that are expected to influence Nanomedicine Market performance and also their seriousness of impacting market growth within the span of assessment interval.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2734725&source=atm

In addition to evaluation of dynamics, the report supplies In-depth examination of key business trends that are anticipated to behave more prominently in global Nanomedicine Market. The study also provides valued information concerning the present and upcoming growth opportunities in Nanomedicine Market the important players and new market entrants can capitalize on.

Competitive Businesses And manufacturers in global market

segment by Type, the product can be split intoQuantum dotsNanoparticlesNanoshellsNanotubesNanodevicesMarket segment by Application, split intooncologyInfectious diseasesCardiologyOrthopedicsOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2734725&source=atm

Opportunity assessment offered in this Nanomedicine Market report Is important in terms of understanding the lucrative regions of investment, which prove to be the actionable insights for major market players, providers, distributors, and other stakeholders in Nanomedicine Market.

In-depth global Nanomedicine Market taxonomy presented in this Report offers detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional evaluation of global Nanomedicine Market divides global market landscape into essential geographies.

Regional prognosis and country-wise analysis of Nanomedicine Market Allows for the analysis of multi-faceted operation of marketplace in all of the crucial markets. This information intends to provide a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Taxonomy and geographic analysis of the international Nanomedicine Market enables readers to see profits in present chances and catch upcoming growth chances even until they approach the market location. The analysis given in report is only meant to unroll the economic, societal, regulatory and political situations of this market specific to each area and country, which could help potential market entrants in Nanomedicine Market landscape to comprehend the nitty-gritty of target market areas and invent their plans accordingly.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2734725&licType=S&source=atm

Nanomedicine Market Table of Contents

View original post here:
Nanomedicine Market 2019 by Rising-Trends, Growth Analysis, Industry Share, Product Types, User-Demand, Business Strategy and Comprehensive Valuation...

This report presents the worldwide Healthcare Nanotechnology (Nanomedicine) market size (value, production and consumption), splits the breakdown (data status 2018 and forecast to 2025), by manufacturers, region, type and application.

This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Top Companies in the Global Healthcare Nanotechnology (Nanomedicine) Market:

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

The report provides a valuable source of insightful data for business strategists and competitive analysis of Healthcare Nanotechnology (Nanomedicine) Market. It provides the Healthcare Nanotechnology (Nanomedicine) industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Healthcare Nanotechnology (Nanomedicine) study provides comprehensive data which enhances the understanding, scope and application of this report.

Influence of the Healthcare Nanotechnology (Nanomedicine) market report:

-Comprehensive assessment of all opportunities and risk in the Healthcare Nanotechnology (Nanomedicine) market.

Healthcare Nanotechnology (Nanomedicine) market recent innovations and major events.

-Detailed study of business strategies for growth of the Healthcare Nanotechnology (Nanomedicine) market-leading players.

-Conclusive study about the growth plot of Healthcare Nanotechnology (Nanomedicine) market for forthcoming years.

-In-depth understanding of Healthcare Nanotechnology (Nanomedicine) market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Healthcare Nanotechnology (Nanomedicine) market.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

The report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Study Coverage

1.1 Healthcare Nanotechnology (Nanomedicine) Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size Growth Rate by Type

1.4.2 Hydraulic Dredges

1.4.3 Hopper Dredges

1.4.4 Mechanical Dredges

1.5 Market by Application

1.5.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size Growth Rate by Application

2 Executive Summary

2.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size

2.1.1 Global Healthcare Nanotechnology (Nanomedicine) Revenue 2014-2025

2.1.2 Global Healthcare Nanotechnology (Nanomedicine) Production 2014-2025

2.2 Healthcare Nanotechnology (Nanomedicine) Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Key Healthcare Nanotechnology (Nanomedicine) Manufacturers

2.3.2.1 Healthcare Nanotechnology (Nanomedicine) Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Healthcare Nanotechnology (Nanomedicine) Product Offered

2.3.2.3 Date of Manufacturers Enter into Healthcare Nanotechnology (Nanomedicine) Market

2.4 Key Trends for Healthcare Nanotechnology (Nanomedicine) Markets & Products

3 Market Size by Manufacturers

3.1 Healthcare Nanotechnology (Nanomedicine) Production by Manufacturers

3.1.1 Healthcare Nanotechnology (Nanomedicine) Production by Manufacturers

3.1.2 Healthcare Nanotechnology (Nanomedicine) Production Market Share by Manufacturers

3.2 Healthcare Nanotechnology (Nanomedicine) Revenue by Manufacturers

3.2.1 Healthcare Nanotechnology (Nanomedicine) Revenue by Manufacturers (2019-2025)

3.2.2 Healthcare Nanotechnology (Nanomedicine) Revenue Share by Manufacturers (2019-2025)

3.3 Healthcare Nanotechnology (Nanomedicine) Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

See the rest here:
Increase in the Adoption of Healthcare Nanotechnology (Nanomedicine) to Propel the Growth of the Healthcare Nanotechnology (Nanomedicine) Market...

Nanomedicine Market Overview 2020 2025

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Nanomedicine Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/91246

Key Competitors of the Global Nanomedicine Market are: , GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A,

Historical data available in the report elaborates on the development of the Nanomedicine on national, regional and international levels. Nanomedicine Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Major Applications of Nanomedicine covered are:Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

This study report on global Nanomedicine market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://reportsinsights.com/discount/91246

The fundamental purpose of Nanomedicine Market report is to provide a correct and strategic analysis of the Nanomedicine industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Nanomedicine market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Nanomedicine-Market-91246

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the original post here:
New Comprehensive Report on Nanomedicine Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like - Jewish Life News

The Healthcare Nanotechnology (Nanomedicine) market report [6 Years Forecast 2020-2026] focuses on the COVID19 Outbreak Impact analysis of key points influencing the growth of the market. Providing info like market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the Top Key Players of Healthcare Nanotechnology (Nanomedicine), with sales, revenue and global market share of Healthcare Nanotechnology (Nanomedicine) are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Healthcare Nanotechnology (Nanomedicine) market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

The study encompasses profiles of major companies operating in the global Healthcare Nanotechnology (Nanomedicine) market. Key players profiled in the report includes : Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International, and among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Healthcare Nanotechnology (Nanomedicine) Market @https://www.researchmoz.us/enquiry.php?type=S&repid2041239

The Healthcare Nanotechnology (Nanomedicine) market report provides a comprehensive analysis of:Industry overview, cost structure analysis, technical data and competitive analysis, topmost players analysis, development trend analysis, overall market overview, regional market analysis, consumers analysis and marketing type analysis.

Scope of Healthcare Nanotechnology (Nanomedicine) Market:

The global Healthcare Nanotechnology (Nanomedicine) market is valued at million US$ in 2019 and will reach million US$ by the end of 2026, growing at a CAGR of during 2020-2026. The objectives of this study are to define, segment, and project the size of the Healthcare Nanotechnology (Nanomedicine) market based on company, product type, application and key regions.

This report studies the global market size of Healthcare Nanotechnology (Nanomedicine) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Healthcare Nanotechnology (Nanomedicine) in these regions.

This research report categorizes the global Healthcare Nanotechnology (Nanomedicine) market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, customers, research findings & conclusion, appendix & data source and Porters Five Forces Analysis.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate foreach application.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2041239

(*Fill the form and our sales representative will get back to you for assistance)

Healthcare Nanotechnology (Nanomedicine) Market The Regional analysis covers:

Key Takeaways and Reasons To Buy Healthcare Nanotechnology (Nanomedicine) Market Report:

And Many More.Contact Us:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

See the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Share, Revenue, And Average Worth By Makers Shared In An Exceedingly Latest Analysis Report - Cole of...

Global Radiocontrast Agent Market: Competitive Analysis

The latest report on the globalRadiocontrast Agent marketpublished by theMarket Data Analyticsprovides a comprehensive study of the Radiocontrast Agent market. This research study includes historical data from 2015-2018 and the forecast from 2019 to 2026. The Radiocontrast Agent report covers the latest impact ofCOVID-19on the Radiocontrast Agent market. The pandemic has affected every market around the globe in a negative way. As the world still struggles to recover from the COVID-19 situation it will take a long time for every market to recover its losses. The latest report on the global Radiocontrast Agent market provides you with each and every details about the Radiocontrast Agent market, that is, the current and the future market scenario along with how it was in the past few years.

Request a sample copy of this report::https://www.marketdataanalytics.biz/worldwide-radiocontrast-agent-market-report-2020-industry-analysis-size-40083.html#request-sample

As per our research analysts the impact of COVID-19 has strongly affected the future market opportunities, revenue growth graph, and the profit gains of the business. The report on the global Radiocontrast Agent market consists of more than 25 tables and above 30 figures. The complete report includes more than 150 pages and is available in PDF format.

The research on the Radiocontrast Agent market includes the latest opinions of the market experts as to how the market has been affected by COVID-19 and how the market scenario has changed in the past four months. The research analysts have done a thorough research and have achieved the latest market numbers and the compound annual growth rate.

Read Full Research Report@https://www.marketdataanalytics.biz/worldwide-radiocontrast-agent-market-report-2020-industry-analysis-size-40083.html

The report details are segregated into the market overview, scope of the market, research methodologies used, market drivers, restraints, opportunities, and challenges. The other quantitative and qualitative data includes the market segmentation, regional bifurcation, and the profiling of the industry players.

The market is segmented into{Barium-based Radiocontrast Agent, Iodinated Radiocontrast Agent, Gadolinium-based Radiocontrast Agent, Microbubble Radiocontrast Agent};{Radiology, Interventional Radiology, Interventional Cardiology}. The geographical presence of the Radiocontrast Agent market is categorized mainly into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Some of the major industry players included within the Radiocontrast Agent market study includesGE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South.

The data provided in the global Radiocontrast Agent market is highly accurate and reliable thus enabling the client to better understand the current market size and position.

If Any Inquiry of Radiocontrast Agent Report:https://www.marketdataanalytics.biz/worldwide-radiocontrast-agent-market-report-2020-industry-analysis-size-40083.html#inquiry-for-buying

Benefits of Buying this Market Research Report:

1.Analyst advocacy:Get correct answers of your queries from our analysts team of experts before and after purchasing the report.2.Meet Customers Requirements:Our expert team will assist with all your research requirements and customize the report.3.Unique Expertise:We centre around the quality standards and reliability of the report.4.One of a kind Expertise:Experts will give splendid bits of knowledge about the report.

Read the original here:
Global Radiocontrast Agent Market 2020 with Coronavirus (COVID-19) Impact Analysis | likewise Industry is Booming Globaly with Top Players GE...

Accidental discoveries have always led to intriguing research in science, and one such incident by a group of researchers has been published in the journal American Chemical Society.

Image Credit:Billion Photos/Shutterstock.com

Polymeric nanoparticles have so far been proven to be useful for biomedical applications such as for the fabrication of nanostructures; however, their natural function for biological activities has not received much attention. This article will uncover the natural disposition of polymeric nanoparticles for function in biological activities such as targeting submandibular salivary glands.

A major challenge within drug delivery and nanomedicine consist of the ability to target specific tissues.

While there have been increased efforts in this area by innovative researchers through enhancing the selectivity of current nanomedicine drug delivery systems as well as novel strategies to increase targeting, this challenge has not yet been overcome.

The field of nanomedicine thus far has attempted to target specific tissues by utilizing ligands to identify and recognize receptors located on tissue-specific cells. This has resulted in ligands such as antibodies, peptides, aptamers, and others being conjugated onto nanoparticle surfaces, allowing functionalization and increasing the specificity of drug delivery systems. Still, with complex designs, there is difficulty translating a ready-made product for clinical use.

The use of unmodified nanoparticles with intrinsic biological activities could be potentially used to decrease the level of processing required for a fully functional and functionalized drug delivery system. This has made biological macromolecules such as peptides, nucleic acids, and proteins desirable due to their natural ability to have specific molecular interactions with tissues.

Additionally, synthetic polymers can also be exploited for this purpose. They also possess the ability to have interactions for targeting biological functions due to moieties that selectively interact with targets to interfere with their operations.

However, with polymeric nanoparticles being widely used as a drug carrier in nanomedical research, the use of these specialized particles would be useful for the purpose of tissue targeting.

Researchers within this particular study found that polyethyleniminepoly(lactic-co-glycolic acid)2(PEIPLGA), usually used in gene and protein delivery, can mediate the targeting of submandibular salivary glands of mice after being intravenously injected for in vivo experimentation.

The research team found that unmodified polyethyleniminepoly(lactic-co-glycolic acid)2(PEIPLGA) nanoparticles with the hydrophilic PEI fully exposed on the surface around the aqueous phase could selectively accumulate in these mice submandibular salivary glands due to a high affinity with acetylcholine receptors in the specific tissue.

This is comparable to FDA-approved drugs such as muscarinic acetylcholine receptor subtype 3 (M3 receptor)-binding drugs. This illustrates the potential similarity in efficacy, a promising step for a novel drug system utilizing nanomedicine in the form of polymeric nanoparticles for gene targeting.

PEIPLGA nanoparticles can adsorb many negatively charged biological molecules such as RNA, protein, and DNA and have already been commonly utilized for the delivery of nucleic acid or protein drugs through nonselective static electric attraction.

However, the novel aspect of this particular research focused on PEI-PLGA nanoparticles being able to interact with the M3 acetylcholine receptor, which is expressed in a large volume in the submandibular salivary glands.

The development of synthetic polymers such as PEI-PLGA nanoparticles for biological applications can illustrate the interaction of polymers and proteins and can aid in the development of design strategies for nanomedical drug systems.

Additionally, this research would be useful for the development of M3 receptor-targeted therapies to enhance the treatment of diseases relating to the expression of the M3 receptor. An example of such a disorder includes Sjgren syndrome (SS), an autoimmune disease that affects exocrine glands, including salivary and lacrimal glands.

This receptor is also overexpressed in other organs such as the brain, with cholinergic transmission at muscarinic acetylcholine receptors being critical for higher brain function, including learning and memory and a loss of synapses resulting in symptoms relating to Alzheimers disease.

However, while this potential for brain treatment for motor neuron diseases can be technically possible, further research is required as few PEI-PLGA nanoparticles have been observed in the brain, which may be due to the blood-brain barrier.

The researchers have theorized that other muscarinic receptor subtypes such as M1 receptors are also overexpressed in the submandibular gland, so improving the selectivity of PEI-PLGA to target these subtypes can also be a research point.

While no obvious change was found in the level of salivary secretion within mice injected with PEI-PLGA nanoparticles within 24 hours, the targeting ability of these novel polymeric nanoparticles for biological activities is a promising start for possible interference in M3 signaling pathways and function.

This research can be exploited for many useful applications as summarized above and further illustrates the significance of nanomedicine in advancing diseases.

Continue reading: Green Synthesis of Ag Nanoparticles for Antibacterial Applications.

Haam, J. and Yakel, J., (2017)Cholinergic modulation of the hippocampal region and memory function.Journal of Neurochemistry, 142, pp.111-121. Available at: https://doi.org/10.1111/jnc.14052

Heller Brown, J. and Laiken, N., (2012)Acetylcholine and Muscarinic Receptors.Primer on the Autonomic Nervous System, pp.75-78. Available at: https://doi.org/10.1016/B978-0-12-386525-0.00015-9

Xu, J., Wan, K., Wang, H., Shi, X., Wang, J., Zhong, Y., Gao, C., Zhang, Y. and Nie, G., (2021)PolyethyleniminePoly(lactic-co-glycolic acid)2 Nanoparticles Show an Innate Targeting Ability to the Submandibular Salivary Gland via the Muscarinic 3 Receptor.ACS Central Science, 7(11), pp.1938-1948. Available at: https://doi.org/10.1021/acscentsci.1c01083

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Read more here:
Polymeric Nanoparticles and the Future of Gene Delivery Methods - AZoNano

Endo International

Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=210503&utm_source=COD&utm_medium=888

Global Healthcare Nanotechnology (Nanomedicine) Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Healthcare Nanotechnology (Nanomedicine) sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Healthcare Nanotechnology (Nanomedicine) sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Healthcare Nanotechnology (Nanomedicine) sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Healthcare Nanotechnology (Nanomedicine) market and formulate optimal business strategies to maximize market growth.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=210503&utm_source=COD&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Healthcare Nanotechnology (Nanomedicine) market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Healthcare Nanotechnology (Nanomedicine) market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Healthcare Nanotechnology (Nanomedicine) Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Healthcare Nanotechnology (Nanomedicine) Market Size, Healthcare Nanotechnology (Nanomedicine) Market Growth, Healthcare Nanotechnology (Nanomedicine) Market Forecast, Healthcare Nanotechnology (Nanomedicine) Market Analysis

More:
Healthcare Nanotechnology (Nanomedicine) Market Analysis by Size, Share, Top Key Manufacturers, Demand Overview, Regional Outlook And Growth Forecast...

Scientists have found that a new knee injection using nanomedicine could prevent the effects of osteoarthritis.

A group of scientists have discovered a potential method to cure osteoarthritis. According to the researchers, a simple knee injection could stop the diseases effects. The study was conducted at the University of Pennsylvania, US.

The researchers showed that they could target a specific protein pathway in mice to halt cartilage degeneration over time. Building on that finding, they were able to show that treating mice with surgery-induced knee cartilage degeneration through the same pathway via nanomedicine could dramatically reduce the cartilage degeneration and knee pain.

Our lab is one of the few in the world studying epidermal growth factor receptor (EGFR) signalling in cartilage and from the beginning, we have found that EGFR deficiency or inactivation accelerates osteoarthritis progression in mice, said one of the researchers Associate Professor Ling Qin. Thus, we proposed that its activation could be used to treat osteoarthritis and in this study, we have proven for the first time that over-activating it inside the knee blocks the progression of osteoarthritis.

The researchers compared typical mice with those that had a ligand that bound to EGFR that was over-overexpressed in chondrocytes, the building blocks of cartilage. This overexpression drives the over-activation of EGFR signalling in knee cartilage. When examining them, the mice with overexpressed HBEGF (the EGFR ligand) were found to consistently have enlarged cartilage, meaning that it was not wearing away like the mice who had normal EGFR activity. Moreover, when these mice aged to adulthood, their cartilage was resistant to degeneration and other hallmarks of osteoarthritis, even if their knees meniscus was damaged.

To further prove that the over-activated EGFR was the reason for the mices resiliency, the researchers found that gefitinib treatments, which are designed to block EFGR function, took away the protection against cartilage degeneration.

In a new series of tests, the researchers created nanotherapeutics by attaching a potent EGFR ligand, transforming growth factor-alpha, onto synthetic nanoparticles, to inject into mice who already had cartilage damage in their knees.

Free EGFR ligands have a short half-life and cannot be retained inside of a joint capsule due to their small size, explained Associate Professor Zhiliang Cheng, the co-corresponding authors on the paper. Nanoparticles help to protect them from degradation, restrict them within the joint, reduce off-target toxicity and carry them deep inside dense cartilage to reach chondrocytes.

When mice were injected with these nanotherapeutics, the researchers saw that they slowed cartilage degeneration and bone hardening, as well as eased knee pain. There also were no major side effects seen in the mice who were treated.

While many of the technical aspects of this application still need to be worked out, the ability to stop or slow the course of osteoarthritis with an injection rather than surgery would dramatically change how we feel and function as we age and after injury, said one of the studys co- authors, Dr Jaimo Ahn.

There is a great unmet medical need for a disease-modifying osteoarthritis drug, Qin said. In the future, we will optimise the drug design and test it in large animals before proceeding to clinical trials. We hope our research could lead to a novel drug that will improve the health and well-being of the more than 27 million osteoarthritis patients in the US.

The findings were published in Science Translational Medicine.

Excerpt from:
Knee injection shows promise as osteoarthritis treatment in mice - Drug Target Review

The Report Titled onCancer Nanomedicine Market Report- Development Trends, Market Size, Industry Opportunities and Competitive Landscape in 2021firstly introduced the Cancer Nanomedicine Industry basics:The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors.The report takes into account theimpact of the COVID-19 pandemic on the Cancer Nanomedicine marketand is perfect for precision and accuracy that will help to meet business requirements at affordable rates. By using Cancer Nanomedicine market report, strengths and weaknesses as well as threats and opportunities for the business can be known. Defining the problem and objectives, collecting and generating market data with the supporting statistics, everything is performed in a streamlined process which makes this report highly accurate.

The information of Cancer Nanomedicine market analysis report covers major technological, scientific and economic developments in industrial, pharmaceutical and high technology organizations. This large scale report helps to achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Market Analysis and Insights: Global Cancer Nanomedicine Market:

Cancer nanomedicine market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 12.50% in the above-mentioned forecast period.

Get more information on Global Cancer Nanomedicine Market Research Report by requesting FREE Sample Copy at:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-nanomedicine-market&AS

The major players who are leading the Cancer Nanomedicine market throughout the globe are:

Market Segmentation

By Type (Inorganic Nanoparticles, Organic Nanoparticles)

By Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents)

Some Of The Major Highlights Of TOC Covers:-

1 INTRODUCTION

1.1 Objectives Of The Study

1.2 Cancer Nanomedicine Market Definition

2 MARKET SEGMENTATION

2.1 Cancer Nanomedicine Markets Covered

2.2 Europe Weight Management Market: Geographical Scope

3 MARKET OVERVIEW

3.1 Drivers

4 EXECUTIVE SUMMARY

4.1 Europe Weight Management Market: Segmentation

5 PREMIUM INSIGHTS

5.1 Increasing Government Initiatives Towards Management And Growing Consumption Of Healthy Diets Are Expected To Drive The Cancer Nanomedicine Market In The Forecast Period Of 2020 To 2027

Continued.

Browse Global Cancer Nanomedicine Market Research Report with detailed TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-nanomedicine-market&AS

Global Cancer Nanomedicine Market Scope and Market Size

Cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for Cancer Nanomedicine market across This section covers regional segmentation which accentuates on current and future demand for COVID-19 Cancer Nanomedicine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions. Further, the report focuses on demand for individual application segment across all the prominent regions.

Get detailed COVID-19 impact analysis on the Cancer Nanomedicine Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-nanomedicine-market&AS

Key Pointers Covered In The Cancer Nanomedicine Market Industry Trends And Forecast To 2027

The study provides an in-depth analysis, current trends, and future estimations of theglobal Cancer Nanomedicine marketto elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the Cancer Nanomedicine market growth is provided.

The Cancer Nanomedicine Industry report provides a qualitative and quantitative analysis of the current External Storage market trends, forecasts, and market size from 2020 to 2027 to determine new opportunities.

Porters Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Extensive analyses of key segments of the industry help understand the types of products and technologies used across various geographical regions.

About Data Bridge Market Research Private Ltd:

Data Bridge Market Research PvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact:

Data Bridge Market Research

US:+1 888 387 2818

UK:+44 208 089 1725

Hong Kong:+852 8192 7475

Email:-Corporatesales@databridgemarketresearch.com

See the rest here:
Global Cancer Nanomedicine Market Booming Demand Leading To Exponential CAGR Growth By 2027 The Courier - The Courier

Clene Nanomedicine, one of Marylands Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $31.9 million that will be used to advance the companys gold nanocrystal-based treatment for neurodegenerative diseases.

Clene is developing a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals, which are used to amplify bioenergetic reactions in patients in order to drive intracellular biological reactions. Chief Executive Officer Rob Etherington said bioenergetic nanotherapeutics are a clean break from pharmaceutical drug development that uses classical synthetic chemistry.

Using gold as a therapeutic is not a new concept. Gold-salt injections were historically used to treat rheumatoid arthritis decades ago, but were dropped due to health concerns and toxicity issues.

Funds from the merger with Tottenham, a special purpose acquisition company (SPAC), will be used to advance Clenes lead asset, CNM-Au8, a bioenergetic nanocatalyst under development as an add-on treatment for neurodegenerative diseases like Parkinsons disease, multiple sclerosis and Amyotrophic Lateral Sclerosis (ALS). CNM-Au8 is designed to catalyze biocelluar reactions and so far the company has seen the asset live up to its promise in clinical studies.

Although Clenes corporate offices are in Utah, the bulk of the companys research is conducted in Cecil County, Maryland. Approximately three-fourths of the companys employees are located in Maryland, Etherington said. The company conducts all R&D and manufacturing in Maryland, as well as its commercialization activities.

Maryland has been a perfect anchor for Clene, Etherington said.

While the company raised a significant amount of funds through the merger, Etherington said Maryland was one of the companys earliest financial backers through a loan arrangement. He said predicted his company and the state will continue to have a strong relationship in the years ahead.

The state has been a true supporter. It was also gratifying to be recognized as a Future 2020 company because we have built a home in Maryland, he said.

Etherington predicted the next 18 months will be important for the company due to a planned readout of the companys asset. The funds raised in the merger will be used to carry CNM-Au8 into Phase II and Phase III studies that aim to address neurodegenerative diseases of high unmet medical need, such as multiple sclerosis, Parkinsons disease and amyotrophic lateral sclerosis (ALS). CNM-Au8 is currently being assessed in a Phase II study for the treatment of chronic optic neuropathy in patients with multiple sclerosis and is in Phase II and Phase III studies for disease progression in patients with ALS. Both Phase II studies are expected to read out this year. Its also being studied in a Phase II Parkinsons disease trial. The company reported interim data from the study last year and additional data is expected in the first half of 2021. Clene also plans to launch an additional Phase IIb Parkinsons disease efficacy study with CN<-Au8 by the end of the year.

While CNM-Au8 is showing promise, its not designed to replace any medication currently being used by a patient for one of these diseases. Rather, its designed to work alongside those medications. Clenes compound is designed to enhance the intracellular biological actions necessary to repair and reverse neuronal damage, Etherington said.

Clenes gold nanocrystals are grown in treated water and patients drink the product when it is ready. By combining the nanocrystal therapy with ongoing treatments for these neurodegenerative diseases, Etherington said the goal is to reverse neurodegeneration.

We want to let the cell take care of its own housekeeping and enhance whats naturally occurring in the central nervous system, he said.

In addition to the gold nanocrystal compound, Clene is developing a silver and zinc asset for COVID-19. CNM-AgZn17 is Clenes second key asset intended for broad anti-viral and anti-microbial use. A Phase II study is planned in Brazil to treat acutely symptomatic non-hospitalized patients with COVID-19.

Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.

See original here:
Clene Nanomedicine Aims to be the Gold Standard in Neurodegenerative Disease - BioBuzz

Visit the News Hub

Rheumatologist develops nanomedicine approaches for inflammatory diseases

Christine Pham, MD, works in her lab in 2017. A rheumatologist who specializes in nanomedicine approaches to inflammatory diseases, Pham has been named the inaugural Guy and Ella Mae Magness Professor of Medicine at Washington University School of Medicine in St. Louis.

Christine Pham, MD, director of the Division of Rheumatology at Washington University School of Medicine in St. Louis, has been named the inaugural Guy and Ella Mae Magness Professor of Medicine.

Pham was chosen for the honor in recognition of her work involving nanomedicine approaches in the treatment of inflammatory diseases and the role of biomolecules known as proteases in inflammatory processes. The Department of Medicine established the Guy and Ella Mae Magness Professorship in Medicine in 2018 with proceeds from the Ella Mae Magness Trust.

I am delighted to recognize Dr. Phams accomplishments with this professorship named for two noted health professionals and graduates of Washington University, said Chancellor Andrew D. Martin. Dr. Guy and Ella Mae Magness worked tirelessly to promote public health, and their dedication to medicine and to our community is reflected in Dr. Pham. She has distinguished herself both in her research on the role of neutrophil proteases in inflammatory arthritis and her commitment to mentoring and supporting junior faculty.

Pham will be officially installed when the COVID-19 pandemic is under control. She will be installed by David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean of the School of Medicine, and the Spencer T. and Ann W. Olin Distinguished Professor; and Victoria J. Fraser, MD, the Adolphus Busch Professor of Medicine and head of the Department of Medicine.

Also a professor of pathology & immunology, Pham more recently has focused on nanomedicine approaches for various inflammatory conditions including rheumatoid arthritis, a chronic, incapacitating disease involving painful, swollen joints. Nanomedicine involves using tiny transport particles for a concentrated delivery of therapeutics directly to specific sites such as the joints. Nanoparticle formulations also help protect unstable drugs from degradation in the bloodstream, thereby unlocking the potential of new kinds of therapeutics. Pham employs a nanocomplex that protects an unstable experimental arthritis drug and efficiently delivers it to the joints, where it suppresses specific and harmful pathways that cause inflammation in diseased tissues without affecting the global immune system.

Christine Pham exemplifies faculty who are the foundation of what we do at the School of Medicine today and are poised to do tomorrow, Perlmutter said. She is an outstanding physician-scientist with expertise in immunology, rheumatology and translational approaches to inflammatory arthritis and autoimmune diseases. She draws upon this broad expertise to promote multidisciplinary research in inflammatory diseases with the goal of developing better treatments for patients.

Pham directs Washington Universitys Rheumatic Diseases Research Resource-Based Center, which provides resources to accelerate basic and translational research into rheumatic diseases, aiming to improve treatment for people suffering from rheumatic diseases such as arthritis, lupus and vasculitis, an inflammation of the blood vessels.

Before moving into nanomedicine, Pham explored the role of proteases enzymes that break down proteins produced by certain white blood cells in inflammatory diseases. Her laboratory cloned and characterized the protease cathepsin C. Her work led to the development of cathepsin C inhibitors that are in clinical trials for a form of chronic inflammatory lung disease.

Dr. Christine Phams work on the role of innate and adaptive immune responses in various inflammatory processes has led to the identification of new therapeutic targets for these diseases, Fraser said. She is an esteemed member of the Washington University community who has a deep commitment to innovative multidisciplinary research. She is an outstanding mentor and champion for residents, fellows and junior faculty. She is well-deserving of this recognition.

Guy N. Magness, MD, (1899-1982) earned his medical degree at the School of Medicine in 1928. He began his career as a school physician and in 1931 rose to become director of medical services for University City Public Schools, where he served for 40 years. He also held the position of director of health for University City from 1952 to 1981, gaining recognition as a leader in the field of health problems in public education. In 1963, he co-chaired a polio vaccination drive, and more than a million St. Louisans were immunized as a result. He was in the Army Medical Corps in World War II and retired from the Army reserve as a colonel.

Ella Mae Magness (1905-2000) was Missouris director of public health from the late 1930s to the early 1940s. In the late 1940s, she was the western regional director of public health covering seven states. She earned a certificate in nursing in 1928 and a bachelors degree in nursing in 1937, both from Washington University School of Nursing. She earned a masters degree in public health from Columbia University in New York, and she served in the U.S. Armys Nurse Corps during World War II, attaining the rank of lieutenant colonel.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Continued here:
Pham named Guy and Ella Mae Magness Professor of Medicine - Washington University School of Medicine in St. Louis

TheGlobal Continuous Venovenous Hemofiltration (CVVH) Product Markethas witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2020-2027). The research presents a complete assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry-validated market data.

Continuous Venovenous Hemofiltration (CVVH) Product Market report presents a detailed analysis of the parent market based on elite players, present, past and futuristic data which will serve as a profitable guide for all the industry competitors. Top players in the industry includeGE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), Magnus Health (India).

Click to get a FREE Sample PDF Copy Here:https://www.stratagemmarketinsights.com/sample/584

The Continuous Venovenous Hemofiltration (CVVH) Product Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure, and all these together will help leading players understand the scope of the market. The study also coversmarket status, share, future patterns, development rate, deals, SWOT analysis, channels, merchants, and improvement gets ready for the anticipated year between 2020-2027.

The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. The rapidly changing industry scenario and initial and future assessment of the impact are covered in the report. The Continuous Venovenous Hemofiltration (CVVH) Product market report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction.

It aims to strategically analyze the market with respect to individual growth trends, prospects, and their contribution to the market. The report attempts to forecast the market size for 5 major regions, namely,North America, Europe, Asia Pacific (APAC), Middle East, and Africa (MEA), and Latin America.This report helps to identify the key growth countries and regions.

What Continuous Venovenous Hemofiltration (CVVH) Product Market report offers?

1. Continuous Venovenous Hemofiltration (CVVH) Product Market share assessments for the regional and country-level segments2. Market share analysis of the top industry players3. Continuous Venovenous Hemofiltration (CVVH) Product Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)4. Strategic recommendations in key business segments based on the market estimations5. Competitive landscape covering the following points:Company Overview, Product Portfolio, Financial Performance, Recent Highlights, Strategies

In the end, the Continuous Venovenous Hemofiltration (CVVH) Product report offers a short outline of the dealers, distributors, suppliers. Along with the Continuous Venovenous Hemofiltration (CVVH) Productsales channel, analysis findings, conclusions, and results. Finally, provide info regarding new entrants within the Continuous Venovenous Hemofiltration (CVVH) Product market. The study suggests a brand new proposition to spice up Continuous Venovenous Hemofiltration (CVVH) Product market price and nurture businesses. Correspondingly explains the current global Continuous Venovenous Hemofiltration (CVVH) Product market and the coming development of the business.

Any customization with this report, please get in touch with SMI experts athttps://www.stratagemmarketinsights.com/quiry/584

Contact Us:

Name: Mr. ShahPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Visit Our Blog:Shubham

Go here to see the original:
Continuous Venovenous Hemofiltration (CVVH) Product Market: Innovative trends with next largest revenue-generating business opportunity by 2027 - The...

This article was originally published here

Med Res Rev. 2020 Dec 21. doi: 10.1002/med.21759. Online ahead of print.

ABSTRACT

Targeted delivery by either passive or active targeting of therapeutics to the bone is an attractive treatment for various bone related diseases such as osteoporosis, osteosarcoma, multiple myeloma, and metastatic bone tumors. Engineering novel drug delivery carriers can increase therapeutic efficacy and minimize the risk of side effects. Developmnet of nanocarrier delivery systems is an interesting field of ongoing studies with opportunities to provide more effective therapies. In addition, preclinical nanomedicine research can open new opportunities for preclinical bone-targeted drug delivery; nevertheless, further research is needed to progress these therapies towards clinical applications. In the present review, the latest advancements in targeting moieties and nanocarrier drug delivery systems for the treatment of bone diseases are summarized. We also review the regeneration capability and effective delivery of nanomedicines for orthopedic applications.

PMID:33347711 | DOI:10.1002/med.21759

View original post here:
Targeted nanomedicines for the treatment of bone disease and regeneration - DocWire News

The Healthcare Nanotechnology (Nanomedicine) Market was valued at US$ XX million in 2019 and is projected to reach US$ XX million by 2025, at a CAGR of XX% during the forecast period. In this study, 2019 has been considered as the base and 2020 to 2025 as the forecast period to estimate the market size for Healthcare Nanotechnology (Nanomedicine) Market

Deep analysis about Healthcare Nanotechnology (Nanomedicine) market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Healthcare Nanotechnology (Nanomedicine) Market.

Get a Sample Copy of the Global Healthcare Nanotechnology (Nanomedicine) Market Report at: https://i2iresearch.com/report/healthcare-nanotechnology-(nanomedicine)-market-report-global-regional-industry-forecast-2019-2024/#download-sample

The Healthcare Nanotechnology (Nanomedicine) Market can be split based on product types, major applications and regions.

By Disease:Cardiovascular DiseasesOncological DiseasesNeurological DiseasesOrthopedic DiseasesInfectious DiseasesOther Diseases

Key Applications:1. Drug Delivery2. Biomaterials3. Active Implants4. Diagnostic Imaging5. Tissue Regeneration6. Other

Healthcare Nanotechnology (Nanomedicine) Market Key companies covered / Analyzed in the report are:

Sanofi SACelegene CorporationCytImmune Sciences Inc.Johnson & JohnsonLuminex CorporationMerck & Co. Inc.NanobiotixPfizer Inc.Starpharma Holdings LimitedTaiwan Liposome Company Ltd

The Healthcare Nanotechnology (Nanomedicine) Market report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/healthcare-nanotechnology-(nanomedicine)-market-report-global-regional-industry-forecast-2019-2024/

Key questions Answered in the report:1. What is the current size of the Healthcare Nanotechnology (Nanomedicine) Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Healthcare Nanotechnology (Nanomedicine) Market?4. What is the likely market forecast & how will be impacted Healthcare Nanotechnology (Nanomedicine) Market?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Healthcare Nanotechnology (Nanomedicine) Market?

The report also analysis the impact of COVID 19 based on a scenario based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

https://neighborwebsj.com/

See the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to...